104290-44-0

Basic information

• Product Name: 5-BROMO-N,N-DIETHYL-3-PYRIDINECARBOXAMIDE
• Synonyms: 5-BROMO-N,N-DIETHYL-3-PYRIDINECARBOXAMIDE;5-BroMo-N,N-diethylnicotinaMide;5-bromo-N,N-diethylpyridine-3-carboxamide
• CAS NO: 104290-44-0
• Molecular Formula: C₁₀H₁₃BrN₂O
• Molecular Weight: 257.13
• Mol File: 104290-44-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-BROMO-N,N-DIETHYL-3-PYRIDINECARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-N,N-DIETHYL-3-PYRIDINECARBOXAMIDE(104290-44-0)
• EPA Substance Registry System: 5-BROMO-N,N-DIETHYL-3-PYRIDINECARBOXAMIDE(104290-44-0)

Safety Data

• Hazardous Substances Data: 104290-44-0(Hazardous Substances Data)

Upstream product

• 39620-02-5 5-bromonicotinoyl chloride 
• 109-89-7 diethylamine 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 98555-51-2 5-Bromo-pyridine-2,3-dicarboxylic acid 
• 98278-78-5 3-bromofuro[3,4-b]pyridine-5,7-dione 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel Bcr-AblT315I inhibitors incorporating amino acids as flexible linker

Despite the success of imatinib in CML therapy through Bcr-Abl inhibition, acquired drug resistance occurs over time in patients. In particular, the resistance caused by T315I mutation remains a challenge in clinic. Herein, we embarked on a structural optimization campaign aiming at discovery of novel Bcr-Abl inhibitors toward T315I mutant based on previously reported dibenzoylpiperazin derivatives. We proposed that incorporation of flexible linker could achieve potent inhibition of Bcr-AblT315I by avoiding steric clash with bulky sidechain of Ile315. A library of 28 compounds with amino acids as linker has been developed and evaluated. Among them, compound AA2 displayed the most potent activity against Bcr-AblWT and Bcr-AblT315I, as well as toward Bcr-Abl driven K562 and K562R cells. Further investigations indicated that AA2 could induce apoptosis of K562 cells and down regulate phosphorylation of Bcr-Abl. In summary, the compounds with amino acid as novel flexible linker exhibited certain antitumor activities, providing valuable hints for the discovery of novel Bcr-Abl inhibitors to overcome T315I mutant resistance, and AA2 could be considered as a candidate for further optimization.

ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY

Provided herein are ergoline-derived heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.

NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME

A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar-B- group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R5, R6, R7, and R8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar-B'- group (B' is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an -NR4- group (R4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R4' is hydrogen atom, or a group represented by the aforementioned formula (a) (R3" and R4" represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]